TEL-AVIV, Israel, Jan. 2, 2024 /PRNewswire/ — Israel Acquisitions Corp. (NASDAQ: ISRL) (NASDAQ: ISRLU) (NASDAQ: ISRLW) (“ISRL”) , a publicly-traded special purpose acquisition company, and Pomvom Ltd.(TASE: PMVM) (“Pomvom” or the “Company”), a technology company that develops experiential content to amusement parks and attractions globally, replacing operative physical solutions, today announced a definitive business combination… Continue reading Pomvom Ltd. and Israel Acquisitions Corp. Announce Definitive Business Combination Agreement, Bringing the Leading Experiential Content Company to the Nasdaq
Category: Newswire
Thailand welcome 2024 at CentralWorld, Times Square of Asia – The only one World’s Entertainment Countdown Landmark of All Time in the Heart of Bangkok
BANGKOK, Jan. 2, 2024 /PRNewswire/ — Central Pattana plc, Thailand’s number one real estate developer and operator of 39 Central shopping centers nationwide, in collaboration with leading public and private partners including the Tourism Authority of Thailand, Bangkok Metropolitan Administration Royal Thai Police and Ratchaprasong Square Trade Association (RSTA), etc., created a sensational world-class countdown event,… Continue reading Thailand welcome 2024 at CentralWorld, Times Square of Asia – The only one World’s Entertainment Countdown Landmark of All Time in the Heart of Bangkok
Harnessing the Transformative Power of Cold Chain Logistics with SSI Schaefer
SINGAPORE and DUBAI, UAE and RIYADH, Saudi Arabia, Jan. 2, 2024 /PRNewswire/ — As average global temperatures rise and the demand for cold-chain storage grows worldwide, SSI Schaefer, a global leader in intralogistics and automated warehouses, is sharing best practices and key considerations on how logistics and operations managers can optimize efficiency and cost-effectiveness of… Continue reading Harnessing the Transformative Power of Cold Chain Logistics with SSI Schaefer
Bybit Web3 Manta Network ile Ortak Oldu ve 100K MANTA Karnavalını Kutluyor
DUBAİ, BAE, 5 Ocak 2024 /PRNewswire/ — Hacim olarak dünyanın en büyük üçüncü borsası olan Bybit, sıfır bilgi (ZK) uygulama ekosistemlerinde öncü olan Manta Network ile heyecan verici bir ortaklığı duyurmanın heyecanını yaşıyor. Ayrıca, topluluğa son teknoloji ürünü ZK teknolojisini tanıtmak ve heyecan verici ödülleri dağıtmak için kutlama amaçlı 100K MANTA Karnavalını da birlikte gerçekleştiriyorlar. Continue… Continue reading Bybit Web3 Manta Network ile Ortak Oldu ve 100K MANTA Karnavalını Kutluyor
Bybit Web3 вместе с Manta Network проводит карнавал 100K MANTA Carnival
ДУБАЙ, ОАЭ, 5 января 2024 г. /PRNewswire/ — Bybit, третья в мире по объему операций криптовалютная биржа с восторгом объявляет о потрясающем партнерстве с Manta Network, пионером в области экосистем приложений с нулевым разглашением (ZK). Вместе они также начнут праздничное мероприятие 100K MANTA Carnival, чтобы представить сообществу современнейшую технологию ZK и объявить впечатляющие премии. Continue Reading… Continue reading Bybit Web3 вместе с Manta Network проводит карнавал 100K MANTA Carnival
Bybit Powered by Satos Enhances “One Click Buy” to Offer the Best Rates for Crypto Purchases via EUR in Netherlands
AMSTERDAM, Jan. 5, 2024 /PRNewswire/ — Bybit powered by Satos, the world’s third largest crypto exchange by volume, is thrilled to unveil a significant enhancement to its “One Click Buy” features in the Netherlands. This latest upgrade offers users a seamless and expeditious transaction process with a substantial reduction in costs for crypto purchases via… Continue reading Bybit Powered by Satos Enhances “One Click Buy” to Offer the Best Rates for Crypto Purchases via EUR in Netherlands
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington’s disease Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with participation from Polaris Partners, Pureos Bioventures and Eurazeo LEIDEN, Netherlands, Jan. 5, 2024 /PRNewswire/ —… Continue reading Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Vico Therapeutics maakt een Serie B-financiering van $60 miljoen (€54 miljoen) bekend om het VO659 klinische-fase programma voor zeldzame neurologische ziekten te bevorderen en nieuwe mogelijkheden uit te breiden
De financiering ondersteunt lopend Fase 1/2a klinisch onderzoek waarin VO659 wordt geëvalueerd bij patiënten met spinocerebellaire ataxie type 3 en type 1 en de ziekte van Huntington. De financiering werd geleid door Ackermans & van Haaren samen met Droia Ventures, EQT Life Sciences en Kurma Partners, met deelname van Polaris Partners, Pureos Bioventures en Eurazeo. LEIDEN, Nederland,… Continue reading Vico Therapeutics maakt een Serie B-financiering van $60 miljoen (€54 miljoen) bekend om het VO659 klinische-fase programma voor zeldzame neurologische ziekten te bevorderen en nieuwe mogelijkheden uit te breiden
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 5, 2024 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD);formulation of nanoenzalutamide and Xtandi®[1], the number one prescribed androgen receptor… Continue reading Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
HELSINKI , Jan. 5, 2024 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD);formulation of nanoenzalutamide and Xtandi®[1], the number one prescribed androgen receptor… Continue reading Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide